The purpose of this study is to demonstrate, in 2-10 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Primary Outcome Measures:
- Occurrence of any grade 3 systemic symptoms [ Time Frame: During the 4-day follow-up period after vaccination, in all subjects ] [ Designated as safety issue: Yes ]
- Vaccine response to meningococcal antigens [ Time Frame: One month after vaccination, in a subset of subjects ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Meningococcal rSBA titres [ Time Frame: Prior to and one month after vaccination, in a subset of subjects ] [ Designated as safety issue: No ]
- Anti-Tetanus toxoid antibody concentrations [ Time Frame: Prior to and one month after vaccination, in a subset of subjects ] [ Designated as safety issue: No ]
- Anti-meningococcal polysaccharide concentrations. [ Time Frame: Prior to and one month after vaccination, in a randomized subset of subjects ] [ Designated as safety issue: No ]
- Occurrence of solicited local and general symptoms [ Time Frame: During the 4-day follow-up period after vaccination, in all subjects ] [ Designated as safety issue: Yes ]
- Occurrence of unsolicited symptoms [ Time Frame: Up to one month after vaccination, in all subjects ] [ Designated as safety issue: Yes ]
- Occurrence of serious adverse events [ Time Frame: Up to six months after vaccination, in all subjects ] [ Designated as safety issue: Yes ]
- Occurrence of specific adverse events of rash, new onset of chronic illness(es) and conditions prompting emergency room visits and physician office visits not related to common illnesses [ Time Frame: Up to six months after vaccination, in all subjects ] [ Designated as safety issue: Yes ]
Enrollment: |
1505 |
Study Start Date: |
September 2007 |
Study Completion Date: |
September 2008 |
Primary Completion Date: |
September 2008 (Final data collection date for primary outcome measure) |
Group B: Active Comparator
|
Biological: Mencevax™
Single dose, subcutaneous injection
|
Group A: Experimental
|
Biological: Meningococcal vaccine GSK134612
Single dose, intramuscular injection
|
Multicentre study with 2 treatment groups. Two blood samples will be taken, prior to and one month after vaccination, from the first 75% enrolled subjects per country independent of the treatment group.